Medical Oncology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Clin Transl Oncol. 2024 Sep;26(9):2388-2392. doi: 10.1007/s12094-024-03467-8. Epub 2024 Apr 1.
Limited data exist on the prognostic significance of the chronology of VTE in patients with PDAC.
Medical data and survival characteristics of patients treated for PDAC from 2019 to 2021 were retrospectively reviewed. Early VTE was defined as occurring within the three months of PDAC diagnosis.
197 patients were included, 54 (27.4%) developed a VTE. Early appearance of VTE was associated with worse prognosis: median overall survival (mOS) VTE < 3 months 8.5 months (HR 1.65, 95% CI 1.11-2.46; p = 0.014), mOS VTE > 3 months 12.8 months (HR 0.78, 95% CI 0.39-1.54; p = 0.5) and mOS patients without VTE 11.4 months (95% CI 10.1-15.4). There was no significant association between the patient's VTE risk according to the Khorana risk score (KRS) (chi2 test p-value = 0.9).
Early VTE is a prognostic factor in PDAC, which may identify a more aggressive subtype.
关于 PDAC 患者 VTE 发生的时间顺序的预后意义，目前数据有限。
回顾性分析了 2019 年至 2021 年期间接受 PDAC 治疗的患者的医疗数据和生存特征。早期 VTE 定义为 PDAC 诊断后三个月内发生。
共纳入 197 例患者，其中 54 例（27.4%）发生了 VTE。VTE 的早期出现与预后较差相关：VTE<3 个月的中位总生存期（mOS）为 8.5 个月（HR 1.65，95%CI 1.11-2.46；p=0.014），VTE>3 个月的 mOS 为 12.8 个月（HR 0.78，95%CI 0.39-1.54；p=0.5），无 VTE 的患者 mOS 为 11.4 个月（95%CI 10.1-15.4）。根据 Khorana 风险评分（KRS），患者 VTE 风险之间无显著关联（卡方检验 p 值=0.9）。
早期 VTE 是 PDAC 的预后因素，可能识别出更具侵袭性的亚型。
